866-997-4948(US-Canada Toll Free)

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Sep 2013

Category :

Head and Neck Cancer

No. of Pages : 140 Pages

 

Global Markets Directs, \'Head And Neck Cancer Squamous Cell Carcinoma Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma. Head And Neck Cancer Squamous Cell Carcinoma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

 

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Scope

 

  • A snapshot of the global therapeutic scenario for Head And Neck Cancer Squamous Cell Carcinoma.
  • A review of the Head And Neck Cancer Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Head And Neck Cancer Squamous Cell Carcinoma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

 

Reasons to buy

 

  • Identify and understand important and diverse types of therapeutics under development for Head And Neck Cancer Squamous Cell Carcinoma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Head And Neck Cancer Squamous Cell Carcinoma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents


Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Head And Neck Cancer Squamous Cell Carcinoma Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma 10
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics under Development by Companies 12
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Discovery and Pre-Clinical Stage Products 18
Comparative Analysis 18
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics - Products under Development by Companies 19
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics - Products under Investigation by Universities/Institutes 20
Companies Involved in Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Development 21
F. Hoffmann-La Roche Ltd. 21
Shionogi & Co., Ltd. 22
Amgen Inc. 23
AstraZeneca PLC 24
Eli Lilly and Company 25
Viralytics Ltd. 26
GlaxoSmithKline plc 27
Gilead Sciences, Inc. 28
Celltrion, Inc. 29
Novartis AG 30
Eisai Co., Ltd. 31
ImmunoGen, Inc. 32
Idera Pharmaceuticals, Inc. 33
Cleveland BioLabs, Inc. 34
Cancer Research Technology Limited 35
Acceleron Pharma, Inc. 36
Glycotope GmbH 37
Crusade Laboratories Limited 38
Onconova Therapeutics, Inc 39
Gliknik, Inc. 40
Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Combination Products 42
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 47
IMO-2055 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
cetuximab - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
vandetanib - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
dalantercept - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
gefitinib - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
entolimod - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
rigosertib sodium - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
panitumumab - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
CVA-21 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
lapatinib ditosylate - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
imgatuzumab - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
nimotuzumab - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
LY-2606368 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Dendritic Cell Vaccine - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
raltegravir potassium + [cisplatin] - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
cetuximab biosimilar - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Anti-CD-147 Antibody - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
LJM-716 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Seprehvir - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
nimorazole - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
GL-0810 - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
GL-0817 - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
interleukin-15 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
IMGN-289 - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
Antibody Against FERM Domain-Containing Protein 4A - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
LOXL4 Monoclonal Antibody - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
T4 Immunotherapy - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
AZ-64 - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
SHetA-2 - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics - Drug Profile Updates 108
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics - Discontinued Products 131
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics - Dormant Products 132
Head And Neck Cancer Squamous Cell Carcinoma - Product Development Milestones 133
Featured News & Press Releases 133
Jun 02, 2013: Symphogen Reports New Data On Anti-EGFR Monoclonal Antibody Mixture At ASCO 2013 Annual Meeting 133
May 30, 2013: Symphogen To Report New Data On Anti-EGFR Monoclonal Antibody Mixture At ASCO 134
Apr 11, 2013: Navidea Biopharma Presents Top-Line Interim Analysis Of Lymphoseek From Phase III Study At InternationaI Symposium On Thoracic And Upper Aerodigestive Malignancies 135
Apr 10, 2013: ImmunoGen Announces Preclinical Findings With IMGN289 Product Candidate For Treatment Of EGFR-Overexpressing Cancers 136
Apr 04, 2013: Navidea Biopharma Announces Positive Top-line Results From Interim Analysis Of Lymphoseek Phase III Clinical Trial In Head And Neck Cancer 137
 

Appendix 139
Methodology 139
Coverage 139
Secondary Research 139
Primary Research 139
Expert Panel Validation 139
Contact Us 140
Disclaimer 140

List of Table


Number of Products Under Development for Head And Neck Cancer Squamous Cell Carcinoma, H2 2013 10
Products under Development for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis, H2 2013 11
Number of Products under Development by Companies, H2 2013 13
Number of Products under Investigation by Universities/Institutes, H2 2013 14
Comparative Analysis by Late Stage Development, H2 2013 15
Comparative Analysis by Mid Clinical Stage Development, H2 2013 16
Comparative Analysis by Early Clinical Stage Development, H2 2013 17
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 18
Products under Development by Companies, H2 2013 19
Products under Investigation by Universities/Institutes, H2 2013 20
F. Hoffmann-La Roche Ltd., H2 2013 21
Shionogi & Co., Ltd., H2 2013 22
Amgen Inc., H2 2013 23
AstraZeneca PLC, H2 2013 24
Eli Lilly and Company, H2 2013 25
Viralytics Ltd., H2 2013 26
GlaxoSmithKline plc, H2 2013 27
Gilead Sciences, Inc., H2 2013 28
Celltrion, Inc., H2 2013 29
Novartis AG, H2 2013 30
Eisai Co., Ltd., H2 2013 31
ImmunoGen, Inc., H2 2013 32
Idera Pharmaceuticals, Inc., H2 2013 33
Cleveland BioLabs, Inc., H2 2013 34
Cancer Research Technology Limited, H2 2013 35
Acceleron Pharma, Inc., H2 2013 36
Glycotope GmbH, H2 2013 37
Crusade Laboratories Limited, H2 2013 38
Onconova Therapeutics, Inc, H2 2013 39
Gliknik, Inc., H2 2013 40
Assessment by Monotherapy Products, H2 2013 41
Assessment by Combination Products, H2 2013 42
Assessment by Stage and Route of Administration, H2 2013 44
Assessment by Stage and Molecule Type, H2 2013 46
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics - Drug Profile Updates 108
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics - Discontinued Products 131
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics - Dormant Products 132

List of Chart


Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma, H2 2013 10
Products under Development for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis, H2 2013 11
Products under Development by Companies, H2 2013 12
Products under Investigation by Universities/Institutes, H2 2013 14
Late Stage Products, H2 2013 15
Mid Clinical Stage Products, H2 2013 16
Early Clinical Stage Products, H2 2013 17
Discovery and Pre-Clinical Stage Products, H2 2013 18
Assessment by Monotherapy Products, H2 2013 41
Assessment by Combination Products, H2 2013 42
Assessment by Route of Administration, H2 2013 43
Assessment by Stage and Route of Administration, H2 2013 44
Assessment by Molecule Type, H2 2013 45
Assessment by Stage and Molecule Type, H2 2013 46

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *